US Edition
Cordis initiates SELUTION global coronary registry of coronary DCB - Cardiovascular News
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Cordis initiates SELUTION global coronary registry of coronary DCB - Cardiovascular News
Cordis has announced the initiation of the SELUTION global coronary registry, a prospective study enrolling up to 10,000 patients worldwide, assessing the company’s Selution SLR coronary drug-coated balloon (DCB). The registry will track real-world outcomes of the device for up to five years and will complement the results from the on-going randomised trials. The SELUTION global coronary registry builds upon the five ongoing level 1 randomised t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
